HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors

66Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Germ cell tumors (GCT) are strictly associated with the expression of HERV-K(HML-2) proviruses, and the majority of GCT patients produce antibodies to structural proteins of these proviruses. The objective of our study was to determine the significance of the serological response to HERV-K(HML-2) Gag and Env proteins for diagnosis, management of GCT patients and estimation of the therapy success. The data document a strong association of HERV-K(HML-2) antibodies and the clinical manifestation of the disease and therapy success. HERV-K(HML-2) antibodies seem to have an important diagnostic value as well as indicator of chemotherapy success. © 2004 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Kleiman, A., Senyuta, N., Tryakin, A., Sauter, M., Karseladze, A., Tjulandin, S., … Mueller-Lantzsch, N. (2004). HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. International Journal of Cancer, 110(3), 459–461. https://doi.org/10.1002/ijc.11649

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free